A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs AVB 620 (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions; First in man
- Sponsors Avelas BioSciences
- 08 Dec 2016 Results published in an Avelas BioSciences media release.
- 08 Dec 2016 According to an Avelas BioSciences media release, data from the study has been presented at the San Antonio Breast Cancer Symposium.
- 08 Dec 2016 Status changed from active, no longer recruiting to completed, according to an Avelas BioSciences media release.